SCHEMBL7403188

SCHEMBL7403188

CCOC(=O)CC1=CCCc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CARM1 Q86X55 1/20 0.42
BRD4 O60885 1/20 0.41
NOTUM Q6P988 1/20 0.41
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19985029 0.92 ALDH1A1 (0.45) KDM4EALDH1A1L3MBTL1HPGDTDP1
SCHEMBL3703857 0.85 SMN1; SMN2 (0.42) KDM4EALDH1A1L3MBTL1HPGDTDP1
SCHEMBL31686158 0.85 SMN1; SMN2 (0.42) KDM4EALDH1A1L3MBTL1HPGDTDP1
SCHEMBL24821194 0.82 KDM4C (0.45) BRD4PPARG
SCHEMBL8515359 0.82 MPO (0.51) ALDH1A1L3MBTL1HPGDSMN1; SMN2BRD4
SCHEMBL27366916 0.82 MAPT (0.42) KDM4EALDH1A1L3MBTL1HPGDTDP1
SCHEMBL31618140 0.82 MPO (0.42) BRD4PPARGMPO
SCHEMBL10530875 0.82 MPO (0.42) KDM4EALDH1A1L3MBTL1HPGDTDP1
SCHEMBL7401882 0.82 SIGMAR1 (0.45) KDM4EALDH1A1HPGDNOTUM
SCHEMBL9482430 0.81 MPO (0.64) KDM4EL3MBTL1TDP1SMN1; SMN2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512843-B1 PLANT GROWTH REGULATOR COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2021-10-20 EP disclosed
US-11136292-B2 Plant growth regulator compounds SYNGENTA PARTICIPATIONS AG (CH) 2021-10-05 US disclosed
US-20190330148-A1 PLANT GROWTH REGULATOR COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2019-10-31 US disclosed
WO-2018050477-A1 PLANT GROWTH REGULATOR COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-03-22 WO disclosed
WO-2017208253-A2 AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVACAFTOR COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-12-07 WO disclosed
EP-2730918-B1 MATRIX FOR MALDI MASS SPECTROMETRY AND MALDI MASS SPECTROMETRY METHOD UNIV KYUSHU NAT UNIV CORP (JP) 2016-09-14 EP disclosed
US-20140151548-A1 MATRIX FOR MALDI MASS SPECTROMETRY AND MALDIMASS SPECTROMETRY METHOD KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2014-06-05 US disclosed
EP-2730918-A1 MATRIX FOR MALDI MASS SPECTROMETRY Kyushu University National University Corporation (JP) 2014-05-14 EP disclosed
CN-101429125-A Synthesis of (7-methoxy-3, 4-dihydrogen-1-naphthyl) ethyl acetate SHANGHAI INST PHARM INDUSTRY (CN) 2009-05-13 CN disclosed
US-6133446-A Heterocyclic compounds for the treatment of CNS and cardiovascular disorders PHARMACIA & UPJOHN COMPANY (US) 2000-10-17 US disclosed
CN-1046507-C Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases UPJOHN CO (US) 1999-11-17 CN disclosed
US-5877317-A Heterocyclic compounds for the treatment of CNS and cardiovascular disorders PHARMACIA & UPJOHN COMPANY (US) 1999-03-02 US disclosed
CN-1139431-A Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases PHARMACIA & UPJOHN CO LLC (US) 1997-01-01 CN disclosed
EP-0737189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS PHARMACIA & UPJOHN COMPANY (US) 1996-10-16 EP disclosed
EP-0490772-B1 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them ADIR (FR) 1995-07-26 EP disclosed
WO-1995018118-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS THE UPJOHN COMPANY (US) 1995-07-06 WO disclosed
US-5194437-A Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders ADIR ET COMPAGNIE (FR) 1993-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136292-B2 Plant growth regulator compounds FGF1, MST1, CDC20 KDM4E 3400/4885ALDH1A1 3543/4885L3MBTL1 3472/4885
US-20190330148-A1 PLANT GROWTH REGULATOR COMPOUNDS FGF1, MST1, CDC20 KDM4E 3400/4885ALDH1A1 3543/4885L3MBTL1 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.